Bandingkan Harga & Kinerja Kota Satu Properti Tbk. (SATU) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Kota Satu Properti Tbk. dan Organon Pharma Indonesia Tbk.: Kota Satu Properti Tbk. diperdagangkan di Rp246 (kapitalisasi pasar 343,75 M, volume 24 jam 1,6 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Kota Satu Properti Tbk. jauh lebih besar — sekitar 3,3× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SATU | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 343,75 M | 104,4 M |
Volume | 1,6 jt | — |
Lot | 16,02 rb | — |
Perputaran | 401,74 jt | — |
Harga Rata-rata | 250,71 | — |
Nilai Transaksi | 401,74 jt | — |
Harga Ekuilibrium Indikatif | 246 | — |
Volume Ekuilibrium Indikatif | 108 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Kota Satu Properti Tbk.
PT Kota Satu Properti Tbk (the Company) was established based on Notarial Deed No. 6, dated October 3, 2012 of Maria Yosefa Deni, S.H., notary in Semarang. PT Kota Satu Properti Tbk. is a company the first developer and became a pioneer in introducing the modern housing concept in the city Ungaran, Semarang Regency. Where homeowners are surrounded by the convenience of modern facilities including: club house, lounge, swimming pool, kids playground, RFID gate system, panic button, CCTV & 24hours security, housekeeping & laundry, broadband internet (Wifi), ATMs and minimarkets.
Selengkapnya di halaman SATU →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
